Steven D. Nathan, MD, FCCP ( Moderator) Professor of Medicine Virginia Commonwealth University School of Medicine, Inova Fairfax Campus Director, Inova Advanced Lung Disease Program Medical Director, Inova Lung Transplant Program Falls Church, VA Marilyn K. Glassberg Csete, MD Professor of Medicine, Surgery and Pediatrics Director, Interstitial Lung Disease Program Director, Pulmonary Diseases at Interdisciplinary Stem Cell Institute Vice-Chairman of Medicine for Diversity and Innovation University of Miami, Miller School of Medicine Miami, FL
David J. Lederer, MD, MS Associate Professor Co-Director, Interstitial Lung Disease Program Columbia University Medical Center New York, NY
AMA PRA Category 1 Credit TM
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia, and its diagnosis and management remain a challenge in clinical practice. An expanding body of research on the pathogenesis of IPF, however, is leading to the identification of new therapeutic targets, and best practices are evolving with the emergence of new data and new therapies. This activity, which features a supplemental resource center, will help pulmonology clinicians achieve greater competency in applying evidence-based practices to the diagnosis and treatment of IPF.
. Target Audience
This activity is intended for pulmonologists and other clinicians involved in the treatment of patients with IPF, including nurse practitioners, physician assistants, and nurses.
Upon completion of this educational activity, the participant should be able to:
State the criteria required for a diagnosis of IPF, according to ATS/ERS guidelines.
Monitor patients with IPF for progressive disease.
Develop timely, appropriate therapeutic interventions, including recently approved pharmacologic therapies, pulmonary rehabilitation, lung transplantation, and supportive care.
Discuss current evidence for safety and efficacy of newly approved therapies for IPF and those in late stages of clinical development.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Steven D. Nathan, MD, FCCP, has disclosed the following:
Consultant: Gilead Sciences, Inc.; Genentech; Boehringer Ingelheim Pharmaceuticals, Inc.
Research Grant: Gilead Sciences, Inc.; Genentech; Boehringer Ingelheim Pharmaceuticals, Inc.
Speakers Bureau: Gilead Sciences, Inc.; Genentech; Boehringer Ingelheim Pharmaceuticals, Inc.
Marilyn K. Glassberg Csete, MD, has disclosed the following:
Consultant: Genentech; Boehringer Ingelheim Pharmaceuticals, Inc.; Mesoblast
Research Grant: Genentech
David J. Lederer, MD, MS, has disclosed the following:
Consultant: Gilead Sciences, Inc.; Genentech; Boehringer Ingelheim Pharmaceuticals, Inc.; Pharmakea; UCB; Pulmonary Fibrosis Foundation; France Foundation; Degge Group
Research Grant: Gilead Sciences, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bayer
Penn State staff involved in the development and review of this activity have nothing to disclose.
Kathleen Hines, MCM Education, Vice President, Editorial Services, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling. Credit Statements
Credit is awarded to participants who score 80% or better on the post-test.
The online activity will take approximately 60 minutes to complete.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5896-16-T. Commercial Support Statements
Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, or Boehringer Ingelheim Pharmaceuticals, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.